OBJECTIVES: To evaluate the health benefits, costs and cost-effectiveness of vaccination with Bivalent Respiratory Syncytial Virus Stabilized Prefusion F vaccine (RSVpreF), for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in Greek adults 60 years of age and older

METHODS: A Markov model was adapted to simulate lifetime risk of health and economic outcomes from the public payer’s perspective over a lifetime horizon. Epidemiology, vaccine’s efficacy, utilities and direct medical costs (prices, €2024) data were obtained from published literature, official sources and local experts. Model outcomes included number of medically attended RSV cases, stratified by care setting (i.e., hospital, emergency department [ED], outpatient visit [OV]), and attributable RSV-related deaths, life years (LY) & quality-adjusted life-years (QALY) gained, costs, and incremental cost-effectiveness ratios (ICERs) of RSVpreF vaccination compared to no vaccination.

RESULTS: The model analysis projected that there would be 258,170 hospitalizations, 112,248 ED encounters, 1,201,604 OV and 25,463 deaths related to RSV among Greek older adults resulting in direct medical costs of €1.58 billion over lifetime horizon. Based on RSV vaccination coverage considered in the analysis, the model indicates that 18,118 hospitalizations, 7,874 ED encounters, 48,079 OV and 1,706 deaths could be prevented over the modeled time horizon. The health benefits associated with RSVpreF contributed to incremental gain of 10,976 LYs and 7,230 QALYs compared with no vaccination strategy. The incremental analysis showed that vaccination with RSVpreF was estimated to be a cost-effective strategy resulting in ICERs of €12,991 per LY gained, €19,723 per QALY gained and €7,870 per RSV hospitalized case avoided compared to no vaccination strategy.

CONCLUSIONS: Vaccination with RSVpreF was a cost-effective strategy for the prevention of RSV disease in Greek adults over 60 years. The availability of RSV vaccination improves public health by averting additional RSV cases and deaths and has the potential to fulfill an unmet medical need.